SEC Form SC 13G/A filed by Trinity Biotech plc (Amendment)

2/13/23 1:25:56 PM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $TRIB alert in real time by email

SC 13G/A 1 trib-13g_20221231.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Trinity Biotech plc ---------------------------------------------------------------------------- (Name of Issuer) American Depositary Shares (each representing 4 'A' Ordinary Shares, par value US$0.0109) ---------------------------------------------------------------------------- (Title of Class of Securities) 896438306 ---------------------------------------------------------------------------- (CUSIP Number) December 30, 2022 ---------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [_] Rule 13d-1(c) [_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. 896438306 13G Page 2 of 8 Pages ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only). Renaissance Technologies LLC 26-0385758 ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 1,393,438 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 0 _____________________________ (7) SOLE DISPOSITIVE POWER 1,393,438 _____________________________ (8) SHARED DISPOSITIVE POWER 0 ______________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,393,438 ------------------------------------------------------------------------------ (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ------------------------------------------------------------------------------ (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.66 % ------------------------------------------------------------------------------ (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA Page 2 of 8 pages ============================================================================= Page 3 of 8 pages ----------------------------------------------------------------------------- CUSIP NO. 896438306 13G Page 3 of 8 Pages ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). RENAISSANCE TECHNOLOGIES HOLDINGS CORPORATION 13-3127734 ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 1,393,438 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 0 _____________________________ (7) SOLE DISPOSITIVE POWER 1,393,438 _____________________________ (8) SHARED DISPOSITIVE POWER 0 _____________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,393,438 ----------------------------------------------------------------------------- (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ----------------------------------------------------------------------------- (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.66 % ----------------------------------------------------------------------------- (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC Page 3 of 8 pages ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. 896438306 13G Page 4 of 8 Pages ----------------------------------------------------------------------------- Item 1. (a) Name of Issuer Trinity Biotech plc (b) Address of Issuer's Principal Executive Offices. IDA Business Park, Bray, Co. Wicklow, Ireland Item 2. (a) Name of Person Filing: This Schedule 13G is being filed by Renaissance Technologies LLC ("RTC") and Renaissance Technologies Holdings Corporation ("RTHC"). (b) Address of Principal Business Office or, if none, Residence. The principal business address of the reporting persons is: 800 Third Avenue New York, New York 10022 (c) Citizenship. RTC is a Delaware limited liability company, and RTHC is a Delaware corporation. (d) Title of Class of Securities. Depositary Shares (each representing 4 'A' Ordinary Shares, par value US$0.0109) (e) CUSIP Number. 896438306 Page 4 of 8 pages ============================================================================= Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13-d-2(b) or (c),check whether the person filing is a: (a) [_] Broker or dealer registered under section 15 of the Act. (b) [_] Bank as defined in section 3(a)(6) of the Act. (c) [_] Insurance Company as defined in section 3(a)(19) of the Act. (d) [_] Investment Company registered under section 8 of the Investment Company Act. (e) [x] Investment Adviser in accordance with Sec.240.13d-1(b)(1)(ii)(E). (f) [_] Employee Benefit Plan or Endowment Fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F). (g) [_] Parent holding company, in accordance with Sec.240.13d-1(b)(1)(ii)(G). (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940. (j) [_] Group, in accordance with Sec.240.13d-1(b)(1)(ii)(J). Item 4. Ownership. (a) Amount beneficially owned. RTC: 1,393,438 shares RTHC: 1,393,438 shares, comprising the shares beneficially owned by RTHC, because of RTHC's majority ownership of RTC. (b) Percent of Class. RTC: 3.66 % RTHC: 3.66 % (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: RTC: 1,393,438 RTHC: 1,393,438 (ii) Shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: RTC: 1,393,438 RTHC: 1,393,438 (iv) Shared power to dispose or to direct the disposition of: RTC: 0 RTHC: 0 Page 5 of 8 pages ============================================================================= Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X] Item 6. Ownership of More than Five Percent on Behalf of Another Person. Certain funds and accounts managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable Item 8. Identification and Classification of Members of the Group. Not applicable Item 9. Notice of Dissolution of a Group. Not applicable Page 6 of 8 pages ============================================================================= Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 13, 2023 Renaissance Technologies LLC By: /s/ Brian Felczak Co-Chief Financial Officer Renaissance Technologies Holdings Corporation By: /s/ Brian Felczak Vice President Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001). Page 7 of 8 Pages ============================================================================== EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING UNDER RULE 13D-1(K) OF THE EXCHANGE ACT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the filing on behalf of each of a Statement on Schedule 13G, and all amendments thereto, with respect to the American Depositary Shares (each representing 4 'A' Ordinary Shares, par value US$0.0109) of Trinity Biotech plc. Date: February 13, 2023 Renaissance Technologies LLC By: /s/ Brian Felczak Co-Chief Financial Officer Renaissance Technologies Holdings Corporation By: /s/ Brian Felczak Vice President Page 8 of 8 Pages

Get the next $TRIB alert in real time by email

SEC Form SC 13G/A filed by Trinity Biotech plc (Amendment)

2/13/23 1:25:56 PM ET

$TRIB

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $TRIB alert in real time by email

SEC Form SC 13G/A filed by Trinity Biotech plc (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$TRIB

SEC Form SC 13G/A filed by Trinity Biotech plc (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$TRIB

$TRIB
SEC Filings

SEC Form 6-K filed by Trinity Biotech plc

SEC Form 6-K filed by Trinity Biotech plc

SEC Form 6-K filed by Trinity Biotech plc

$TRIB
Press Releases

New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring

Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

$TRIB
Insider Trading

SEC Form 3 filed by new insider O'Caoimh Ronan

Amendment: SEC Form 3 filed by new insider Gillard John

SEC Form 3 filed by new insider Murphy Paul

$TRIB
Financials

New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring

Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

$TRIB
Leadership Updates

Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations

Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

$TRIB
Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

SEC Form SC 13D/A filed by Trinity Biotech plc (Amendment)

SEC Form SC 13D filed by Trinity Biotech plc

SEC Form SC 13G/A filed by Trinity Biotech plc (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $TRIB

SEC Form SC 13G/A filed by Trinity Biotech plc (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $TRIB

$TRIB SEC Filings

SEC Form 6-K filed by Trinity Biotech plc

SEC Form 6-K filed by Trinity Biotech plc

SEC Form 6-K filed by Trinity Biotech plc

$TRIB Press Releases

New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring

Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

$TRIB Insider Trading

SEC Form 3 filed by new insider O'Caoimh Ronan

Amendment: SEC Form 3 filed by new insider Gillard John

SEC Form 3 filed by new insider Murphy Paul

$TRIB Financials

New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring

Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

$TRIB Leadership Updates

Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations

Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

$TRIB Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

SEC Form SC 13D/A filed by Trinity Biotech plc (Amendment)

SEC Form SC 13D filed by Trinity Biotech plc

Recent Analyst Ratings for
$TRIB

Recent Analyst Ratings for
$TRIB

$TRIB
SEC Filings

$TRIB
Press Releases

$TRIB
Insider Trading

$TRIB
Financials

$TRIB
Leadership Updates

$TRIB
Large Ownership Changes